Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 279 recruiting now early-phase tilt #6 of 28,963 conditions

Cancer: early-phase trial registry

279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #6 of 28,963 conditions by registered trial count.

621 US clinical trials · 279 currently recruiting · #6 of 28,963 conditions by registered trial count

Cancer: 621 US clinical trials tracked, 279 recruiting.

Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.

Open enrollment, early-phase tilt

Cancer has 621 registered US clinical trials, 279 of them open to new participants right now, about 45% of the total.

279
recruiting participants now
45%
of trials open to enrollment
31
in Phase 3-4 (later-stage)
31
top sponsor: M.D. Anderson Cancer Center

Corpus placement: #6 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer is recruiting above its size-band peers.

    279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cancer trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cancer enrolment sits around 108 participants.

    Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.

  4. Cancer research is mostly interventional.

    462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1116Phase 248Phase 327Phase 44

Open and recent trials

621 total, page 12 of 13

COMPLETED NA 30 participants

CancerLife: Patient-Driven Solution in Cancer Care

Saint John's Cancer Institute

NCT03371147

COMPLETED 30 participants

A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression

National Cancer Institute (NCI)

NCT00928382

COMPLETED Phase 1 29 participants

Effect of Samarium on the Relief of Pain Due to Vertebral Metastases

New York Presbyterian Brooklyn Methodist Hospital

NCT00374751

COMPLETED Phase 2 29 participants

Eribulin and Lenvatinib in Advanced Solid Tumors

Virginia G. Kaklamani

NCT02640508

COMPLETED Phase 1 29 participants

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

GlaxoSmithKline

NCT01966445

COMPLETED NA 28 participants

Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors

Emory University

NCT03539835

COMPLETED NA 27 participants

Post-Operative Ambulatory Challenge and Exercise (PACE) Trial

Dana-Farber Cancer Institute

NCT03234933

COMPLETED NA 26 participants

Improving Care Coordination for Adolescents and Young Adults With Cancer

Wake Forest University Health Sciences

NCT04586127

COMPLETED Phase 1 26 participants

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

University of Utah

NCT00708448

COMPLETED Phase 2 26 participants

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

M.D. Anderson Cancer Center

NCT02932332

COMPLETED 26 participants

M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program

M.D. Anderson Cancer Center

NCT00827801

COMPLETED Phase 1 26 participants

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Myrexis

NCT00920205

COMPLETED NA 25 participants

Virtual Reality to Promote Relaxation Prior to Simulation

Abramson Cancer Center at Penn Medicine

NCT06318338

COMPLETED Phase 1 25 participants

A Study of AMG 820 in Subjects With Advanced Solid Tumors

AmMax Bio

NCT01444404

COMPLETED 25 participants

Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors

New Mexico Cancer Research Alliance

NCT00322634

COMPLETED Phase 1 25 participants

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Regeneron Pharmaceuticals

NCT00082823

COMPLETED Phase 2 25 participants

A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00094562

COMPLETED Phase 1 24 participants

A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

AEterna Zentaris

NCT01224730

COMPLETED Phase 1 23 participants

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

GlaxoSmithKline

NCT01954043

COMPLETED Phase 2 23 participants

An Open Label Study of Oral Enzastaurin in Participants With Cancer

Eli Lilly and Company

NCT00309140

COMPLETED NA 23 participants

A Brief Parental Intervention on Learning and Education in Childhood Cancer

University of New Mexi

NCT05268315

COMPLETED Phase 1 23 participants

Study of Irinotecan on a Weekly Schedule in Children

Baylor College of Medicine

NCT00062842

COMPLETED Phase 1 23 participants

Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

Soricimed Biopharma

NCT01578564

COMPLETED NA 22 participants

Faith-Based African American Cancer Survivorship Storytelling

Emory University

NCT03082612

COMPLETED Phase 2 22 participants

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

University of New Mexi

NCT00276003

COMPLETED Phase 3 22 participants

Bintrafusp Alfa Program Rollover Study

EMD Serono Research & Development Institute

NCT05061823

COMPLETED NA 22 participants

Behavioral Activation-Led Activity Engagement for Cancer Empowerment

University of Pittsburgh

NCT06796608

COMPLETED Phase 1 21 participants

Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan

University of New Mexi

NCT00249977

COMPLETED NA 21 participants

Learning Yoga to eNhance Cancer Survivorship

Northwestern University

NCT04301050

COMPLETED NA 20 participants

Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer

University of California, Davis

NCT04594096

COMPLETED Phase 1 20 participants

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

University of Louisville

NCT00509691

COMPLETED NA 20 participants

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Cedars-Sinai Medical Center

NCT05403736

COMPLETED Phase 1 19 participants

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Esanex

NCT02063958

COMPLETED Phase 1 18 participants

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Genentech

NCT02536391

COMPLETED NA 18 participants

Mindfulness Based Smoking Cessation Program

Boston Medical Center

NCT02795312

COMPLETED Phase 1 17 participants

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Dana-Farber Cancer Institute

NCT03495323

COMPLETED Phase 1 17 participants

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

University of California, San Francisco

NCT01235897

COMPLETED 17 participants

Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess

H. Lee Moffitt Cancer Center and Research Institute

NCT00822822

COMPLETED NA 17 participants

Traditional African Healing Ceremony in a U.S. Population

Duke University

NCT01873482

COMPLETED 17 participants

Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles

Memorial Sloan Kettering Cancer Center

NCT00582192

COMPLETED Phase 1 17 participants

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

Esanex

NCT01851096

COMPLETED Phase 1 17 participants

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

MedImmune

NCT00284817

COMPLETED NA 16 participants

Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer

University of Miami

NCT03993054

COMPLETED Phase 1 15 participants

Topotecan Pharmacokinetic Characterization Study

GlaxoSmithKline

NCT00361803

COMPLETED Phase 1 15 participants

[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors

University of Utah

NCT00707343

COMPLETED Phase 1 15 participants

Combination Paclitaxel, Carboplatin and Temozolomide

New Mexico Cancer Research Alliance

NCT00249964

COMPLETED Phase 1 15 participants

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

National Cancer Institute (NCI)

NCT00061347

COMPLETED Phase 1 14 participants

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Albert Einstein College of Medicine

NCT03403049

COMPLETED NA 12 participants

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors

University of Colorado, Denver

NCT05558384

COMPLETED Phase 1 12 participants

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences

NCT01495663

← Previous Page 12 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 116
Phase 2 48
Phase 3 27
Phase 4 4

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Cancer right now

279 recruiting of 621 indexed (45% open).

Phase mix: 31 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top sponsor: M.D. Anderson Cancer Center (31 trials), 9 others listed. 50 shown below, recruiting first. #6 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Cancer?

PlainTrial tracks 621 US clinical trials for Cancer, of which 279 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.